Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 5
2017 7
2018 7
2019 11
2020 8
2021 7
2022 6
2023 6
2024 3
2025 9
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Miller PD, et al. JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. JAMA. 2016. PMID: 27533157 Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) was a phase 3, double-blind, RCT (March 2011-October 2014) at 28 sites in 10 countries. ...Further research is needed to understand the clinical impor …
DESIGN, SETTING, AND PARTICIPANTS: The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) was a phase 3, do …
Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Händel MN, Cardoso I, von Bülow C, Rohde JF, Ussing A, Nielsen SM, Christensen R, Body JJ, Brandi ML, Diez-Perez A, Hadji P, Javaid MK, Lems WF, Nogues X, Roux C, Minisola S, Kurth A, Thomas T, Prieto-Alhambra D, Ferrari SL, Langdahl B, Abrahamsen B. Händel MN, et al. BMJ. 2023 May 2;381:e068033. doi: 10.1136/bmj-2021-068033. BMJ. 2023. PMID: 37130601 Free PMC article.
OBJECTIVE: To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis dru …
OBJECTIVE: To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide …
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG. Bone HG, et al. J Clin Endocrinol Metab. 2018 Aug 1;103(8):2949-2957. doi: 10.1210/jc.2018-00163. J Clin Endocrinol Metab. 2018. PMID: 29800372 Free PMC article. Clinical Trial.
PURPOSE: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). ...CONCLUSIONS: Eighteen months of ABL followed by 24 …
PURPOSE: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (AL …
Abaloparatide.
Gonnelli S, Caffarelli C. Gonnelli S, et al. Clin Cases Miner Bone Metab. 2016 May-Aug;13(2):106-109. doi: 10.11138/ccmbm/2016.13.2.106. Epub 2016 Oct 5. Clin Cases Miner Bone Metab. 2016. PMID: 27920805 Free PMC article. Review.
In the ACTIVE study, a phase 3 fracture prevention trial, 2460 postmenopausal osteoporotic women at high risk for fracture were randomized to receive 18-months of either daily abaloparatide 80 mug s.c., placebo or teriparatide 20 mug s.c. ...Therefore, …
In the ACTIVE study, a phase 3 fracture prevention trial, 2460 postmenopausal osteoporotic women at high risk for fract …
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis.
Gregson CL, Armstrong DJ, Avgerinou C, Bowden J, Cooper C, Douglas L, Edwards J, Gittoes NJL, Harvey NC, Kanis JA, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Tomson J, Vine N, Compston J; National Osteoporosis Guideline Group (NOGG). Gregson CL, et al. Arch Osteoporos. 2025 Sep 8;20(1):119. doi: 10.1007/s11657-025-01588-3. Arch Osteoporos. 2025. PMID: 40921943 Free PMC article.
The National Osteoporosis Guideline Group (NOGG) has updated the revised UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. ...CONCLUSION: The guide …
The National Osteoporosis Guideline Group (NOGG) has updated the revised UK guideline for the assessment and management of osteopo …
Advances in Parathyroid Hormone-based medicines.
Bonnet AL, Aboishava L, Mannstadt M. Bonnet AL, et al. J Bone Miner Res. 2025 Oct 28;40(11):1195-1206. doi: 10.1093/jbmr/zjaf118. J Bone Miner Res. 2025. PMID: 40847810 Review.
Parathyroid hormone analogs, such as teriparatide (PTH(1-34)) and the PTHrP analog abaloparatide, administered once daily, have significant efficacy in stimulating bone formation, making them valuable options for the treatment of osteoporosis. ...Medications, such a …
Parathyroid hormone analogs, such as teriparatide (PTH(1-34)) and the PTHrP analog abaloparatide, administered once daily, have signi …
Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.
Tella SH, Kommalapati A, Correa R. Tella SH, et al. Cureus. 2017 May 31;9(5):e1300. doi: 10.7759/cureus.1300. Cureus. 2017. PMID: 28680788 Free PMC article. Review.
This paper reviews the profile and potential of abaloparatide in the treatment of postmenopausal osteoporosis. This paper is based on clinical trials and a PubMed search. ...Based on the clinical trials, the optimum dose of abal …
This paper reviews the profile and potential of abaloparatide in the treatment of postmenopausal osteoporosis. This pap …
Abaloparatide for the treatment of postmenopausal osteoporosis.
Pietrogrande L, Raimondo E. Pietrogrande L, et al. Drugs Today (Barc). 2018 May;54(5):293-303. doi: 10.1358/dot.2018.54.5.2800621. Drugs Today (Barc). 2018. PMID: 29911694 Review.
It has been approved in the U.S. for the treatment of postmenopausal women with osteoporosis at a high risk for fracture. Abaloparatide is an anabolic agent and it seems to have a potent anabolic activity with reduced effects on bone resorption. ...In …
It has been approved in the U.S. for the treatment of postmenopausal women with osteoporosis at a high risk for fracture. A …
Parathyroid hormone receptor agonists in the management of osteoporosis.
Fuggle N, Rizzoli R, Beaudart C, Cortet B, Curtis EM, Hiligsmann M, Kaufman JM, Veronese N, Albergaria BH, Al-Daghri N, Alokail M, Brandi ML, Bruyère O, Burlet N, Campusano C, Casado E, Cavalier E, Chandran M, Cooper C, D'Amelio P, Dawson-Hughes B, Ebeling PR, Kanis JA, Kurth A, Matijevic R, McCloskey E, McClung M, Mkinsi O, Njeze N, Radermecker RP, Rannou F, Silverman S, Tüzün Ş, Zakraoui L, Reginster JY, Harvey NC. Fuggle N, et al. Nat Rev Rheumatol. 2025 Oct;21(10):599-611. doi: 10.1038/s41584-025-01287-w. Epub 2025 Aug 11. Nat Rev Rheumatol. 2025. PMID: 40790089 Free article. Review.
Intermittent exposure to PTH results in bone formation being greater than bone resorption, and this effect has been harnessed through the development of agonists of the PTH and PTH-related protein type 1 receptor (PTH1R) to treat osteoporosis. Teriparatide, an analogue of …
Intermittent exposure to PTH results in bone formation being greater than bone resorption, and this effect has been harnessed through the de …
The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.
Sone T, Ohnaru K, Sugai T, Yamashita A, Okimoto N, Inoue T, Matsumoto T. Sone T, et al. Arch Osteoporos. 2023 Nov 30;18(1):146. doi: 10.1007/s11657-023-01344-5. Arch Osteoporos. 2023. PMID: 38030806 Free PMC article. Clinical Trial.
Daily subcutaneous injection of 80 mug abaloparatide increased bone mineral density in Japanese patients with osteoporosis at high fracture risk in the ACTIVE-J trial. ...PURPOSE: Abaloparatide (ABL) increased bone mineral density (BMD) in Japan …
Daily subcutaneous injection of 80 mug abaloparatide increased bone mineral density in Japanese patients with osteoporosis at …
64 results